Metraipolis › archive › dc_bb0637887351

Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series… — Europe PMC PMID:41364253

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41364253
DOI
10.1007/s10549-[numero omesso]-4
License (as archived)
solo-consultazione
Archived
2026-11-07T19:14:31.135Z
SHA-256 of the archived text
461f1da3307b92a357ae60770ee1b851abf8af49dfa22e8662dd4c0666151273
Stable URL of this page
https://metraipolis.com/documento/dc_bb0637887351

How to cite

Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series… — Europe PMC PMID:41364253 — Europe PMC (en), https://europepmc.org/article/MED/41364253 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bb0637887351 (Metraipolis archive dc_bb0637887351, sha256 461f1da3307b92a357ae60770ee1b851abf8af49dfa22e8662dd4c0666151273)
BibTeX
@misc{dcbb0637887351,
  title = {Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series… — Europe PMC PMID:41364253},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41364253},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bb0637887351; sha256 461f1da3307b92a357ae60770ee1b851abf8af49dfa22e8662dd4c0666151273},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41364253. Agents can read the archived copy with the MCP tool read_document.